tbuckley/cabot-search huggingface dataset:
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Authors: Marc Fornt‐Suñé, Maria C. Puertas, Javier Martinez‐Picado, Javier García‐Pardo, Salvador Ventura
Journal: Advanced Healthcare Materials (2024)

Abstract The coronavirus disease 2019 (COVID‐19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), continues to challenge global health despite widespread vaccination efforts, underscoring the need for innovative strategies to combat emerging infectious diseases effectively. Herein, LCB1‐NPs and LCB3‐NPs are engineered as a novel class of protein‐only nanoparticles formed through coiled coil‐driven self‐assembly and tailored to interact specifically with the SARS‐CoV‐2 spike protein. The multivalency of LCB1‐NPs and LCB3‐NPs offers a strategy for efficiently targeting and neutralizing SARS‐CoV‐2 both in solution and when immobilized on surfaces. It is demonstrated that LCB1‐NPs and LCB3‐NPs bind to the SARS‐CoV‐2 spike protein's receptor‐binding domain (RBD) with high affinity, effectively blocking the entry of SARS‐CoV‐2 virus‐like particles into angiotensin‐converting enzyme 2 (ACE2)‐coated human cells. The cost‐effectiveness, scalability, and straightforward production process of these protein nanoparticles make them suitable for developing novel anti‐viral materials. Accordingly, it is shown how these nanostructures can be packed into columns to build up economic and highly potent trapping devices for SARS‐CoV‐2 adsorption.
Sprayable Nanocomposites Hydrogel for Wound Healing and Skin Regeneration
Authors: Sihua Li, Meng Luo, Juntang Li, Qian Huang, Bo Lei
Journal: Advanced Healthcare Materials (2024)

Abstract Wound management remains a critical challenge worldwide and imposes a huge financial burden on every nation. Hydrogels are promising for biomedical applications because of their extracellular matrix (ECM) like structure, good biocompatibility and multifunctional bioactivity. However, the poor mechanical properties and inconvenient operation of traditional hydrogels make it difficult to meet the complex and multifaceted needs of clinical practice. In recent years, the multifunctional nanocomposites hydrogel with especially sprayable feature have shown enhanced mechanical properties and facile operation, which enable their huge clinical applications value. A unique and powerful nanocomposite hydrogels (NCH) platform is developed by combining the many advantages of nanomaterials and hydrogels, which can achieve efficient trauma repair. This work reviews important advances on the preparation, functions and applications of sprayable NCH platforms. The challenges and future trends in the field with the aim of providing researchers with clarity on the past, present, and future of the emerging field of sprayable NCH are also proposed in detail.
Linking Metastatic Potential and Viscoelastic Properties of Breast Cancer Spheroids via Dynamic Compression and Relaxation in Microfluidics
Authors: Margherita Tavasso, Ankur D. Bordoloi, Elsa Tanré, Sanne A. H. Dekker, Valeria Garbin, Pouyan E. Boukany
Journal: Advanced Healthcare Materials (2024)

Abstract The growth and invasion of solid tumors are associated with changes in their viscoelastic properties, influenced by both internal cellular factors and physical forces in the tumor microenvironment. Due to the lack of a comprehensive investigation of tumor tissue viscoelasticity, the relationship between such physical properties and cancer malignancy remains poorly understood. Here, the viscoelastic properties of breast cancer spheroids, 3D (in vitro) tumor models, are studied in relation to their metastatic potentials by imposing controlled, dynamic compression within a microfluidic constriction, and subsequently monitoring the relaxation of the imposed deformation. By adopting a modified Maxwell model to extract viscoelastic properties from the compression data, the benign (MCF‐10A) spheroids are found to have higher bulk elastic modulus and viscosity compared to malignant spheroids (MCF‐7 and MDA‐MB‐231). The relaxation is characterized by two timescales, captured by a double exponential fitting function, which reveals a similar fast rebound for MCF‐7 and MCF‐10A. Both the malignant spheroids exhibit similar long‐term relaxation and display residual deformation. However, they differ significantly in morphology, particularly in intercellular movements. These differences between malignant spheroids are demonstrated to be linked to their cytoskeletal organization, by microscopic imaging of F‐actin within the spheroids, together with cell‐cell adhesion strength.
NPM1 inhibits tumoral antigen presentation to promote immune evasion and tumor progression
Authors: Xin Wang, Yangyang Chai, Yuan Quan, Jiaming Wang, Jiaying Song, Wenkai Zhou, Xiaoqing Xu, Henan Xu, Bingjing Wang, Xuetao Cao
Journal: Journal of Hematology & Oncology (2024)

Tumor cells develop multiple mechanisms to facilitate their immune evasion. Identifying tumor-intrinsic factors that support immune evasion may provide new strategies for cancer immunotherapy. We aimed to explore the function and the mechanism of the tumor-intrinsic factor NPM1, a multifunctional nucleolar phosphoprotein, in cancer immune evasion and progression.
<i>DICER1</i>-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Authors: Kris Ann P. Schultz, Alexander T. Nelson, Paige H. R. Mallinger, Anne K. Harris, Junne Kamihara, Shari Baldinger, Kenneth S. Chen, Dinel Pond, Jessica N. Hatton, Anna G. Dybvik, Sarah G. Mitchell, Melissa R. Perrino, Tal Ben-Ami, Denis Kachanov, Yan Su, Chao Duan, Damon R. Olson, Dave Watson, Amanda L. Field, Laura A. Harney, Ann Garrity Carr, A. Lindsay Frazier, Dominik T. Schneider, David B. Wilson, Suzanne P. MacFarland, Peter J. Schoettler, Andrew J. Bauer, Louis P. Dehner, Dana Ashley Hill, Douglas R. Stewart, Yoav H. Messinger
Journal: Clinical Cancer Research (2024)

DICER1-related tumor predisposition increases risk for a spectrum of benign and malignant tumors. In 2018, the International Pleuropulmonary Blastoma (PPB)/DICER1 Registry published guidelines for testing- and imaging-based surveillance of individuals with a known or suspected germline DICER1 pathogenic or likely pathogenic (P/LP) variant. One of the goals of the Registry is to continue to refine these guidelines as additional data become available.
Farm‐dust mediated protection of childhood asthma: Mass cytometry reveals novel cellular regulation
Authors: Claudia Carina Beerweiler, Michael Salvermoser, Johanna Theodorou, Andreas Böck, Franziska Sattler, Paulina Kulig, Vinko Tosevski, Bianca Schaub
Journal: Allergy (2024)

Abstract Background Farm‐dust mediated asthma protection in childhood was replicated in numerous epidemiological studies. Central immune mechanisms are not fully understood. This exploratory study aimed to disentangle underlying immunological regulation of farm‐dust mediated protection in peripheral blood on a single‐cell level. Methods Single‐cell protein expression of in vitro farm‐dust stimulated and unstimulated cells from allergic asthmatics and healthy controls were measured using mass cytometry. Analysis of innate and adaptive cellular proportions (linear regression) and T‐cell proliferation was performed. Functional marker intensity was investigated using Earth Mover's Distance and the Monte Carlo permutation test. Results Farm‐dust stimulation induced cell type‐specific regulation: Key‐features of farm‐dust stimulation comprised opposing regulation of immune‐cell frequencies (downregulated innate cell populations (monocytes/DCs ( p &lt; .001), NK‐cells ( p &lt; .05)) and upregulated adaptive populations (B‐cells, CD4 + T‐cells (both p &lt; .05)), reduced CD4 + CD25 − T‐cell proliferation, and differential cell type‐specific functional marker expression. Following stimulation, functional marker analysis revealed induced activation (CD25) in T‐cells and NK‐T‐cells in both phenotypes even after correction for multiple testing. Cytotoxicity (GZMB) and inflammation (pERK1/2, pp38) related markers were reduced in T‐cells exclusively in asthmatic children. Asthma‐associated markers (Gata3, RORγ, and HLA‐DR) were reduced in T‐ and innate‐ cell populations of asthmatics following stimulation. B‐cells displayed a phenotypically independent increase of diverse functional markers upon farm‐dust stimulation. Conclusions This study mimicking in vivo environmental exposure identified a novel profile of immune‐regulatory markers using mass cytometry demonstrating decreased asthma‐associated markers following farm‐dust stimulation. These findings may be key for further studies on asthma prevention in childhood.
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China
Authors: Xin Du, Xingxian Luo, Lanqiu Liu, Yanlin Cao, Yajuan Zhang, Yi Zhang
Journal: Journal of Hematology & Oncology (2024)

In recent years, cell therapy research and commercialization have significantly accelerated, especially after the US FDA approved CAR-T therapy. While cell therapy now leads immuno-oncology in clinical trials, challenges such as redundant R&D, target clustering, and unmet clinical need remain. Since 2017, China has established a dual-track regulatory framework, facilitating rapid growth in its cell therapy pipeline, making it the second largest in the world. Despite this progress, China faces similar global challenges. Our study covers 2,794 registered cell therapy clinical trials in China, including 2,045 for immune cell, 683 for stem cell, and 66 for other somatic cell. It compares cell therapy products approved in China, the US, EU, and Japan, analyzes the evolving clinical trials landscape, and highlights the characteristics of investigator-initiated trials (IITs) and industry-sponsored trials (ISTs) in China. Our findings indicate that despite the high disease burden and unmet clinical needs for solid tumors in China, over 38% of trials between 2021 and 2023 focused on hematologic malignancies with established targets like CD19 and BCMA. Over 90% of trials are IITs, which show notable clinical differences from ISTs. We recommend that Chinese regulators establish specific guidelines to promote clinical-value-driven research. Stricter regulatory standards should also be implemented to minimize redundant R&D. Additionally, a value-based reimbursement system for within-class targeted cell therapy products may further reduce duplicated R&D efforts. Given the prevalence of IITs, specifying requirements for IITs could create a new pathway to accelerate product development and better address unmet clinical needs in China.
Adaptive transition decisions and identity exploration among transgender and nonbinary persons exposed to gender identity conversion efforts
Authors: Tural Mammadli, Jarrod Call, Brendon T. Holloway, Darren L. Whitfield, N. Eugene Walls
Journal: International Journal of Transgender Health (2024)

Transgender and nonbinary (TNB) persons' healthcare experiences and related transition decisions have received increasing attention in recent years. Growing literature indicates gender non-affirming practices, such as gender identity conversion efforts (GICE), are harmful for the wellbeing of TNB persons. Yet, how exposure to GICE is linked to transition related decisions among TNB persons remains unexplored. This study examines links between GICE and TNB persons' transition decisions and identity exploration, using a conceptual framework that distinguishes adaptive transition decisions (e.g. transition interruptions due to interpersonal coercion) from identity-related transition decisions. This study is a secondary data analysis of the 2015 U.S. Transgender Survey (N = 27,630). Multinomial logistic regression was conducted to examine the relationship between GICE and transition decisions among TNB persons while controlling for demographic covariates. Overall, 13.5% of TNB participants experienced GICE. Participants interrupted their transition due to interpersonal coercion (4.9%), structural factors (2.0%), and identity-related factors (0.4%). Participants with GICE exposure were more likely to report interrupting their transition due to interpersonal coercion than not interrupting their transition. However, GICE-exposed participants did not have a higher chance of identity-related transition interruptions than no interruptions. These findings point to a potentially harmful role GICE may play in the transition decisions of TNB persons. Our analysis adds to evidence indicating the need for banning GICE and calls for a more nuanced understanding, recognition, and respect for TNB persons' non-linear transitioning trajectories. Otherwise, we risk vilifying gender-affirming practices and pathologizing adaptive transitioning decisions of TNB persons.
Patient preferences for intervention in the setting of precursor multiple myeloma
Authors: Catherine R. Marinac, Katelyn Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R. Rebbeck, Urvi A. Shah, Elizabeth K. O’Donnell, Irene M. Ghobrial, Omar Nadeem, Brian L. Egleston
Journal: Blood Cancer Journal (2024)
A Self‐Assembled Transdermal Nanomedicines Incorporating Pendant Disulfides for Non‐Invasive, Synergistic Treatment of Melanoma
Authors: Junjie Zhang, Changkun Peng, Shuya Liu, Zhijie Lian, Jie Zhou, Jingying Li, Huanghao Yang
Journal: Advanced Healthcare Materials (2024)

Abstract Transdermal drug delivery system (TDDS) offers lower systemic toxicity and good patient compliance, making it a promising treatment option for skin‐related cancers. However, physiological barriers in the skin frequently impede the therapeutic efficiency of TDDS. To address this, a unique self‐assembled TDDS that incorporates disulfide pendant groups (termed Sup‐TDDS) is presented. It is formulated with dithiolane‐containing lipoic acid (LA), photosensitizers Ce6, and chemotherapeutic agents trametinib. Pendant disulfide moieties on Sup‐TDDS facilitate thiol‐disulfide exchange reactions with exofacial thiols on cell surfaces, thus enhancing stratum corneum penetration. In contrast to intravenous injection, topical administration of Sup‐TDDS can penetrate deeper into the skin (&gt; 500 µm) and promote drug accumulation in subcutaneous tumors. In a B16F10‐bearing mouse model, Sup‐TDDS treatment demonstrates significant anti‐tumor effects in primary and recurrent melanoma, benefiting from the synergistic effects of Ce6 and trametinib. These results underscore that Sup‐TDDS's transdermal properties allow non‐invasive melanoma therapy, implying the potential of nanodrugs containing pendant disulfides for transdermal treatment of skin illnesses.
Multi-level correlates of oral pre-exposure prophylaxis discontinuation among English and Spanish-speaking transgender women of color in New York City: the TURNNT cohort study
Authors: Alexander Furuya, Asa Radix, Krish J. Bhatt, Adam Whalen, Su Hyun Park, Jessica Contreras, Roberta Scheinmann, Cristina Herrera, Kim Watson, Denton Callandar, John A. Schneider, Sahnah Lim, Chau Trinh-Shevrin, Dustin T. Duncan
Journal: International Journal of Transgender Health (2024)
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Authors: Jennifer K. Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman, Philip C. Caron, Kevin David, Zachary Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Paul Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, M. Lia Palomba, Ralphael Steiner, Robert Stuver, Pallawi Torka, Santosha Vardhana, Andrew D. Zelenetz, Heiko Schoder, Brandon Imber, Joachim Yahalom, Yanming Zhang, Pallavi Galera, Ahmet Dogan, Umut Aypar, Gilles Salles
Journal: Blood Cancer Journal (2024)
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database
Authors: Pierre-Marie Morice, Sabine Khalife-Hachem, Marion Sassier, Véronique Lelong-Boulouard, Alina Danu, Florence Pasquier, Aline Renneville, Charles Dolladille, Jean-Baptiste Micol
Journal: Blood Cancer Journal (2024)
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma
Authors: Annika Werly, Mareike Hampel, Thomas Hielscher, Kosima Zuern, Sophia K. Schmidt, Alissa Visram, Marc S. Raab, Carsten Mueller-Tidow, Hartmut Goldschmidt, Elias K. Mai
Journal: Blood Cancer Journal (2024)
Hypercoagulability in hemoglobinopathies: Decoding the thrombotic threat
Authors: Rayan Bou‐Fakhredin, Maria Domenica Cappellini, Ali T. Taher, Lucia De Franceschi
Journal: American Journal of Hematology (2024)

Abstract Beta (β)‐thalassemia and sickle cell disease (SCD) are characterized by a hypercoagulable state, which can significantly influence organ complication and disease severity. While red blood cells (RBCs) and erythroblasts continue to play a central role in the pathogenesis of thrombosis in β‐thalassemia and SCD, additional factors such as free heme, inflammatory vasculopathy, splenectomy, among other factors further contribute to the complexity of thrombotic risk. Thus, understanding the role of the numerous factors driving this hypercoagulable state will enable healthcare practitioners to enhance preventive and treatment strategies and develop novel therapies for the future. We herein describe the pathogenesis of thrombosis in patients with β‐thalassemia and SCD. We also identify common mechanisms underlying the procoagulant profile of hemoglobinopathies translating into thrombotic events. Finally, we review the currently available prevention and clinical management of thrombosis in these patient populations.
Brown fat ATP-citrate lyase links carbohydrate availability to thermogenesis and guards against metabolic stress
Authors: Ekaterina D. Korobkina, Camila Martinez Calejman, John A. Haley, Miranda E. Kelly, Huawei Li, Maria Gaughan, Qingbo Chen, Hannah L. Pepper, Hafsah Ahmad, Alexander Boucher, Shelagh M. Fluharty, Te-Yueh Lin, Anoushka Lotun, Jessica Peura, Sophie Trefely, Courtney R. Green, Paula Vo, Clay F. Semenkovich, Jason R. Pitarresi, Jessica B. Spinelli, Ozkan Aydemir, Christian M. Metallo, Matthew D. Lynes, Cholsoon Jang, Nathaniel W. Snyder, Kathryn E. Wellen, David A. Guertin
Journal: Nature Metabolism (2024)
SEA-AD is a multimodal cellular atlas and resource for Alzheimer’s disease
Authors: Michael Hawrylycz, Eitan S. Kaplan, Kyle J. Travaglini, Mariano I. Gabitto, Jeremy A. Miller, Lydia Ng, Jennie L. Close, Rebecca D. Hodge, Brian Long, Tyler Mollenkopf, Shoaib Mufti, Nicole M. Gatto, Eric B. Larson, Paul K. Crane, Thomas J. Grabowski, C. Dirk Keene, Ed S. Lein
Journal: Nature Aging (2024)
Inconsistent embryo selection across polygenic score methods
Authors: Shinichi Namba, Masato Akiyama, Haruka Hamanoue, Kazuto Kato, Minae Kawashima, Itaru Kushima, Koichi Matsuda, Masahiro Nakatochi, Soichi Ogishima, Kyuto Sonehara, Ken Suzuki, Atsushi Takata, Gen Tamiya, Chizu Tanikawa, Kenichi Yamamoto, Natsuko Yamamoto, Yukinori Okada, Norio Ozaki, Yukinori Okada
Journal: Nature Human Behaviour (2024)
Inflammasome protein scaffolds the DNA damage complex during tumor development
Authors: Cheng Shen, Abhimanu Pandey, Daniel Enosi Tuipulotu, Anukriti Mathur, Lixinyu Liu, Haoyu Yang, Nilanthi K. Adikari, Chinh Ngo, Weidong Jing, Shouya Feng, Yuwei Hao, Anyang Zhao, Max Kirkby, Melan Kurera, Jing Zhang, Shweta Venkataraman, Cheng Liu, Renhua Song, Justin J.-L. Wong, Ulrike Schumann, Riccardo Natoli, Jiayu Wen, Liman Zhang, Nadeem O. Kaakoush, Si Ming Man
Journal: Nature Immunology (2024)
How to make cardiology clinical trials more inclusive
Authors: Faiez Zannad, Otavio Berwanger, Stefano Corda, Martin R. Cowie, Habib Gamra, C. Michael Gibson, Alexandra Goncalves, Thomas Hucko, Kamlesh Khunti, Maciej Kostrubiec, Bettina Johanna Kraus, Cecilia Linde, Thomas F. Lüscher, Marion Mafham, Richard Mindham, Rebecca F. Ortega, Eva Prescott, Lehana Thabane, Clyde Yancy, André Ziegler, Harriette G. C. Van Spall
Journal: Nature Medicine (2024)
Mapping extrachromosomal DNA amplifications during cancer progression
Authors: Hoon Kim, Soyeon Kim, Taylor Wade, Eunchae Yeo, Anuja Lipsa, Anna Golebiewska, Kevin C. Johnson, Sepil An, Junyong Ko, Yoonjoo Nam, Hwa Yeon Lee, Seunghyun Kang, Heesuk Chung, Simone P. Niclou, Hyo-Eun Moon, Sun Ha Paek, Vineet Bafna, Jens Luebeck, Roel G. W. Verhaak
Journal: Nature Genetics (2024)

To understand the role of extrachromosomal DNA (ecDNA) amplifications in cancer progression, we detected and classified focal amplifications in 8,060 newly diagnosed primary cancers, untreated metastases and heavily pretreated tumors. The ecDNAs were detected at significantly higher frequency in untreated metastatic and pretreated tumors compared to newly diagnosed cancers. Tumors from chemotherapy-pretreated patients showed significantly higher ecDNA frequency compared to untreated cancers. In particular, tubulin inhibition associated with ecDNA increases, suggesting a role for ecDNA in treatment response. In longitudinally matched tumor samples, ecDNAs were more likely to be retained compared to chromosomal amplifications. EcDNAs shared between time points, and ecDNAs in advanced cancers were more likely to harbor localized hypermutation events compared to private ecDNAs and ecDNAs in newly diagnosed tumors. Relatively high variant allele fractions of ecDNA localized hypermutations implicated early ecDNA mutagenesis. Our findings nominate ecDNAs to provide tumors with competitive advantages during cancer progression and metastasis. A pan-cancer genomic analysis finds an increase of extrachromosomal DNA (ecDNA) in treated and metastatic tumors compared to primary, untreated samples, as well as ecDNA features enriched in advanced disease.